Trends in Inflammatory Bowel Disease Therapy 1999 : The Proceedings of a Symposium Organized by AXCAN PHARMA, Held in Vancouver, BC, August 27–29, 1999

This Trends in Inflammatory Bowel Disease Therapy Symposium was held in Vancouver, British Columbia, Canada, 27~29 August 1999. This is the seventh international symposium, sponsored by Axcan Pharma Canada Inc., since the first symposium in 1986. The Canadian Association of Gastroenterology has co-sponsored these symposia since 1990. Each symposium has been published, and reflects and updates the extensive research and education, and the understanding of the mechanisms and treatment of inflammatory bowel disease. From the beginning, Canadian and international experts have been involved, maintaining a consistently high quality, both in their presentations, during discussions, and the subsequent publication of their work. There have been major advances since the symposium held two years ago, and these are presented in this book. In keeping with modern educational practice, objectives are provided, and all presentations were subject to written independent evalu­ ation. All participants are asked to declare any conflicts of interest. MOCOMP and educational credits are available. Front Matter....Pages i-xvi Front Matter....Pages 1-1 Genetics of inflammatory bowel disease: where are we?....Pages 3-12 Genetics of inflammatory bowel disease: why is it important?....Pages 13-22 Genetics of IBD: impact on immune function....Pages 23-35 Front Matter....Pages 37-37 Bacterial factors in inflammatory bowel disease pathogenesis....Pages 39-45 Inflammatory bowel disease: autoimmunity or chronic inflammation?....Pages 46-53 Neutrophil—epithelial interactions, and efforts to down-regulate them, in inflammatory bowel disease....Pages 54-60 Understanding inflammatory bowel disease at the millennium: tentative answers and future questions....Pages 61-69 Front Matter....Pages 71-71 Diagnosis of inflammatory bowel disease: an update....Pages 73-86 Recent developments in the diagnosis and management of paediatric inflammatory bowel disease....Pages 87-95 Inflammatory bowel disease in the elderly....Pages 96-104 Front Matter....Pages 105-105 Induction of remission in ulcerative colitis....Pages 107-116 Remission maintenance in ulcerative colitis....Pages 117-127 Induction therapy for Crohn’s disease....Pages 128-136 Maintenance of remission in Crohn’s disease....Pages 137-144 Front Matter....Pages 145-145 Risk factors and prevalence of bone disease in inflammatory bowel disease....Pages 147-162 Management of low bone mass in patients with inflammatory bowel disease....Pages 163-172 Steroid-induced osteonecrosis in inflammatory bowel disease: Canadian legal status....Pages 173-181 Front Matter....Pages 183-183 Psychotherapy for inflammatory bowel disease: new prospects....Pages 185-193 The use of complementary and alternative medicine by patients with inflammatory bowel disease....Pages 194-200 Gut Inflammation: is there a role for herbal medicines?....Pages 201-206 Front Matter....Pages 183-183 The role of nutrition in the treatment of inflammatory bowel disease....Pages 207-216 Front Matter....Pages 217-217 Antibodies to proinflammatory cytokines....Pages 219-226 Immunomodulation of Crohn’s disease....Pages 227-233 Application of recombinant DNA technology to the identification of novel therapeutic targets in inflammatory bowel disease....Pages 234-251 The use of probiotics in inflammatory bowel disease....Pages 252-258 Back Matter....Pages 259-262 This volume is the proceedings of the symposium `Trends in Inflammatory Bowel Disease Therapy 1999' held in Vancouver, Canada, August 27-29, 1999, and sponsored by the Canadian Association of Gastroenterology, The Crohn's and Colitis Foundation of Canada and Axcan Pharma. It is the seventh international IBD symposium to be held in Canada and focuses on all areas of IBD therapy. Topics include: Genetics; Pathogenesis with reference to the role of autoimmunity, bacterial factors and neutrophil-epithelial interactions; Special clinical problems such as difficult diagnoses and challenges presented by children and the elderly; Bone disease in IBD; An overview of current therapy; A discussion of alternative therapy